Repros Therapeutics Inc. Updates Guidance for Top Line Results From First Pivotal Androxal® Study to Q3 2013

Published: Jan 28, 2013

THE WOODLANDS, Texas, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a revised date for expected clinical results from the first pivotal study, ZA-301, of Androxal® in the treatment of secondary hypogonadism. The Company now plans to provide the data in Q3 2013 instead of Q2 2013.

Back to news